Copenhagen, Denmark - 5 April, 2011 - Topotarget A/S (NASDAQ OMX: TOPO.CO) held
its annual general meeting today at Symbion, Fruebjergvej 3, DK-2100 Copenhagen
Ø.

At the meeting, Chairman of the board, Bo Jesper Hansen, and Chief Executive
Officer, Francois Martelet, gave a report on the company's activities during
the past year. The audited annual report was adopted and a resolution was
passed to discharge the board of directors and the management from liability.
It was resolved that the loss for the year of DKK 55.7 million be carried
forward to next year through recognition in retained earnings.

Bo Jesper Hansen, Anker Lundemose, Ingelise Saunders, Jeffrey H. Buchalter and
Per Samuelsson were re-elected for a period of one year. Deloitte,
Statsautoriseret Revisionsaktieselskab was re-appointed as the company's
auditors.

The proposal to change Article 6(e) was adopted (extension and increase of
authorization to the board of directors to issue warrants). The board of
directors was authorized to purchase treasury shares within a limit of 10% of
the company's share capital at a price corresponding to the listed price
plus/less 5% at the time of the purchase. The proposal for revised general
guidelines for incentive remuneration of the company's board of directors and
management was adopted. The chairman of the meeting was authorized to apply for
registration of the resolutions passed and to make any such amendments thereto
as may be required by the Danish Commerce and Companies Agency as a condition
for registration or approval.

Immediately after the general meeting the board of directors convened and
elected Bo Jesper Hansen as chairman.


Topotarget A/S


For further information, please contact:

Francois Martelet, CEO: Direct: +45 39 17 83 41; Mobile: +45 51
32 83 41

Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28
98 90 55

Annette Lykke, IR Direct: +45 39 17 83 44; Mobile: +45
23 28 98 14



Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO.CO) is a Scandinavian-based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti-neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of chemotherapy, and is currently in a pivotal trial within PTCL
(peripheral T-cell lymphoma) and phase II in cancer of unknown primary site
(CUP). Topotarget's cancer drug targets are HDAC, NAD+, and topoisomerase II.
Totect® is a product on the market developed from Topotarget's drug discovery
technology. Totect® is marketed by the company's own sales specialists in the
US. The European rights to Savene® were divested in March 2010 as a consequence
of the focus to develop and commercialize belinostat. For more information,
please refer to www.topotarget.com.

Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrollment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

Announcement No 07-11 Passing on Topotarget annual general meeting.pdf